/SLRX
SLRX Stock - Salarius Pharmaceuticals, Inc.
Healthcare|BiotechnologyNASDAQ
$0.69+2.09%
+$0.01 (+2.09%) • Dec 19
55
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.75
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for SLRX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.68 – $0.69
TARGET (TP)$0.79
STOP LOSS$0.63
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.40
52W High$108.00
52W Low$0.64
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | $5.23M |
| Gross Profit | N/A | N/A | N/A | N/A | $5.23M |
| Gross Margin | N/A | N/A | N/A | N/A | 100.0% |
| Operating Income | $-5,734,316 | $-12,894,944 | $-31,841,140 | $-12,812,931 | $-7,786,345 |
| Net Income | $-5,575,777 | $-12,542,693 | $-31,607,956 | $-12,768,238 | $-7,352,254 |
| Net Margin | N/A | N/A | N/A | N/A | -140.5% |
| EPS | $-86.85 | $-0.06 | $-221.55 | $-930.00 | $-1500.00 |
Company Overview
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
SLRXBeat Rate
67%
Last 18 quarters
Avg Surprise
-945.4%
EPS vs Estimate
Beats / Misses
12/6
Last 12 quarters
Latest EPS
$-1.81
Q4 2025
EPS Surprise History
Q1 24
+78.2%
$-26.39vs$-121.14
Q2 24
+93.9%
$-49.18vs$-803.60
Q3 24
+95.6%
$-35.53vs$-803.60
Q4 24
-374.6%
$-11.39vs$-2.40
Q1 25
+71.4%
$-9.90vs$-34.65
Q2 25
+57.1%
$-15.44vs$-36.00
Q3 25
+79.5%
$-6.75vs$-33.00
Q4 25
+94.6%
$-1.81vs$-33.60
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 12, 2026 | — | — | — | — |
Q1 2026 | Mar 19, 2026 | — | — | — | — |
Q4 2025 | Nov 14, 2025 | $-33.60 | $-1.81 | +94.6% | ✓ BEAT |
Q3 2025 | Aug 12, 2025 | $-33.00 | $-6.75 | +79.5% | ✓ BEAT |
Q2 2025 | May 14, 2025 | $-36.00 | $-15.44 | +57.1% | ✓ BEAT |
Q1 2025 | Mar 21, 2025 | $-34.65 | $-9.90 | +71.4% | ✓ BEAT |
Q4 2024 | Nov 14, 2024 | $-2.40 | $-11.39 | -374.6% | ✗ MISS |
Q3 2024 | Aug 9, 2024 | $-803.60 | $-35.53 | +95.6% | ✓ BEAT |
Q2 2024 | May 13, 2024 | $-803.60 | $-49.18 | +93.9% | ✓ BEAT |
Q1 2024 | Mar 22, 2024 | $-121.14 | $-26.39 | +78.2% | ✓ BEAT |
Q4 2023 | Nov 9, 2023 | $-128.34 | $-77.96 | +39.3% | ✓ BEAT |
Q3 2023 | Aug 10, 2023 | $-151.12 | $-171.51 | -13.5% | ✗ MISS |
Q2 2023 | May 11, 2023 | $-237.48 | $-267.47 | -12.6% | ✗ MISS |
Q1 2023 | Mar 27, 2023 | $-248.28 | $-339.43 | -36.7% | ✗ MISS |
Q4 2022 | Nov 10, 2022 | $-341.83 | $-296.25 | +13.3% | ✓ BEAT |
Q3 2022 | Aug 8, 2022 | $-329.84 | $-269.87 | +18.2% | ✓ BEAT |
Q2 2022 | May 12, 2022 | $-2.25 | $-389.81 | -17224.9% | ✗ MISS |
Q1 2022 | Mar 10, 2022 | $-299.85 | $-269.87 | +10.0% | ✓ BEAT |
Q4 2021 | Nov 4, 2021 | $-269.87 | $-239.88 | +11.1% | ✓ BEAT |
Q3 2021 | Aug 5, 2021 | $-179.91 | $-209.90 | -16.7% | ✗ MISS |
Latest News
Salarius Pharmaceuticals To Rebrand As Decoy Therapeutics Following Combination, Changes NASDAQ Ticker Symbol To DCOY
➖ NeutralBenzinga•Dec 18, 2025, 12:52 PM
Salarius' Decoy Therapeutics Announces Collaboration To Conduct In Vitro Testing Of Decoy's Peptide Conjugate Fusion Inhibitors Across Several Influenza Strains Including H5N1 Avian Flu
📈 PositiveBenzinga•Dec 1, 2025, 01:03 PM
Salarius Pharmaceuticals Appoints Frederick E. Pierce CEO
➖ NeutralBenzinga•Nov 19, 2025, 09:20 PM
Salarius Pharma Cites Error On S&P CapIQ Platform; Reiterates Active Nasdaq Trading Under SLRX Ticker
➖ NeutralBenzinga•Nov 19, 2025, 07:47 PM
Salarius Pharmaceuticals Says It Became Aware That Certain Financial Market Data Platforms Published That Co. Had Been Delisted From Nasdaq; Information That Co. Had Been Delisted From Nasdaq Is Inaccurate
➖ NeutralBenzinga•Nov 17, 2025, 10:49 PM
Salarius stock slides after pricing $7M offering
📉 NegativeSeeking Alpha•Nov 11, 2025, 05:02 PM
SLRX stock has given up its prior gain. Salarius Pharmaceuticals shares were trading higher after the company announced the pricing of a $7 million underwritten public offering.
➖ NeutralBenzinga•Nov 11, 2025, 03:15 PM
Salarius Pharmaceuticals shares are trading higher after the company announced the pricing of a $7 million underwritten public offering.
📈 PositiveBenzinga•Nov 11, 2025, 02:44 PM
Salarius Prices $7M Public Offering Of 2,514,335 Shares And Pre Funded Warrants To Purchase 2,152,331 Shares Of Common Stock At A Combined Price Of $1.50
➖ NeutralBenzinga•Nov 11, 2025, 02:20 PM
Salarius Pharmaceuticals Regains Nasdaq Compliance
📈 PositiveBenzinga•Oct 13, 2025, 12:47 PM
Salarius Pharmaceuticals shares are trading lower. The company announced it amended its merger terms with Decoy.
📉 NegativeBenzinga•Sep 18, 2025, 02:22 PM
Salarius Pharmaceuticals Amends Merger Terms With Decoy To Set $10.50 Baseline Conversion Price, $3.75 Floor Price For Preferred Stock
➖ NeutralBenzinga•Sep 18, 2025, 11:09 AM
Salarius Pharmaceuticals regains compliance with Nasdaq minimum bid price requirement
📈 PositiveSeeking Alpha•Sep 9, 2025, 12:09 PM
Salarius Pharmaceuticals Regains Nasdaq Compliance
📈 PositiveBenzinga•Sep 9, 2025, 12:02 PM
Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending
➖ NeutralBenzinga•Aug 15, 2025, 11:50 PM
Frequently Asked Questions about SLRX
What is SLRX's current stock price?
Salarius Pharmaceuticals, Inc. (SLRX) is currently trading at $0.69 per share. The stock has moved +2.09% today.
What is the analyst price target for SLRX?
No analyst price targets are currently available for this stock.
What sector is Salarius Pharmaceuticals, Inc. in?
Salarius Pharmaceuticals, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is SLRX's market cap?
Salarius Pharmaceuticals, Inc. has a market capitalization of $0.00 billion, making it a small-cap company.
Does SLRX pay dividends?
No, Salarius Pharmaceuticals, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorATXI
Avenue Therapeutics, Inc.
$0.65
Mkt Cap: $0.0B
ENVB
Enveric Biosciences, Inc.
$5.08
Mkt Cap: $0.0B
GTBP
GT Biopharma, Inc.
$0.76
Mkt Cap: $0.0B
INDP
Indaptus Therapeutics, Inc.
$2.03
Mkt Cap: $0.0B
LIPO
Lipella Pharmaceuticals Inc.
$0.21
Mkt Cap: $0.0B
NKGN
NKGen Biotech, Inc. Common Stock
$0.05
Mkt Cap: $0.0B
PBM
Psyence Biomedical Ltd.
$1.00
Mkt Cap: $0.0B
REVB
Revelation Biosciences, Inc.
$0.89
Mkt Cap: $0.0B
SLXN
Silexion Therapeutics Ltd.
$2.40
Mkt Cap: $0.0B
SPRC
SciSparc Ltd.
$1.46
Mkt Cap: $0.0B
Explore stocks similar to SLRX for comparison